Escitalopram for Agitation in Alzheimer Disease

摘要/项目摘要作为补充 激动症在阿尔茨海默病(AD)中很常见，是患者和照顾者的主要负担。 找到有效的治疗方法是当务之急。S-西塔德是一项安慰剂对照的随机试验，研究 艾司西妥兰治疗阿尔茨海默病患者12周的疗效观察 疾病(AD)在美国和加拿大的25个地点。在用依西他普兰治疗之前， 照顾者接受心理社会干预，只有那些焦虑不是 改善后的患者被分配到药物治疗。患者的症状可以做出反应 为照顾者提供的心理社会干预强调了照顾者痛苦对 阿尔茨海默病患者的神经精神症状，特别是激越。相应地，刻画 照顾者痛苦最有可能影响焦虑的情况将提供 在未来非药物干预AD激越的研究中需要寻求有价值的数据。在……里面 在本增刊中，我们建议对S-Citad的照顾者进行电话访问，以审查 阿尔茨海默病患者照顾者痛苦与神经精神症状之间的关系。 具体地说，我们建议研究“COVID相关因素”(即个人感染、死亡)的作用 朋友或家人、经济困难)、环境因素(即 州/省、获得医院病床的机会、家庭平均收入)、照顾者痛苦以及 S-Citad参与者的神经精神症状。这些措施将是对这些措施的补充 已在S-锡塔德案中使用，从而丰富了S-锡塔德案审判结果的范围 家长研究的目的。具体地说，本补编将允许对以下因素进行深入的审查 与S-西塔德疗法的初始非药理阶段有关。

ABSTRACT/PROJECT SUMMARY FOR SUPPLEMENT Agitation is common in Alzheimer's disease (AD), and a major burden to patients and caregivers. Finding effective treatments is a priority. S-CitAD is a placebo-controlled, randomized trial investigating the efficacy of a 12-week treatment with escitalopram to reduce agitation in patients with Alzheimer's disease (AD) across 25 sites in the United States and Canada. Prior to treatment with escitalopram, caregivers are given a psychosocial intervention, and only those patients whose agitation is not improved are assigned to pharmacologic treatment. That patients' symptoms can respond to psychosocial intervention provided to caregivers underscores the influence of caregiver distress on neuropsychiatric symptoms, and agitation in particular, in patients with AD. Accordingly, characterizing the circumstances under which caregiver distress is most likely to affect agitation would provide valuable data to pursue in future studies of non-pharmacological interventions for agitation in AD. In this supplement, we propose to conduct a telephone interview with S-CitAD caregivers to examine the association between caregiver distress and neuropsychiatric symptoms in individuals with AD. Specifically, we propose to examine the role of “COVID-related factors” (i.e., personally infected, death of friend or family member, economic hardship), environmental factors (i.e. extent of quarantine by state/province, access to hospital beds, average household income), caregiver distress, and neuropsychiatric symptoms on S-CitAD participants. These measures will complement the measures already used in S-CitAD, and thereby enrich the findings of the S-CitAD trial within the scope of the parent study aims. Specifically, this supplement will allow for a penetrating examination of factors that bear relevance to the initial, non-pharmacological phase of S-CitAD treatment.